Education
About Us
Working with TipRanks
Follow Us
Tvardi Therapeutics (TVRD)
NASDAQ:TVRD
Total Valuation
Tvardi Therapeutics has a market cap or net worth of $277.38M. The enterprise value is $156.52M.
Market Cap$277.38M
Enterprise Value$156.52M
Share Statistics
Tvardi Therapeutics has 9,377,433 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding9,377,433
Owned by Insiders13.10%
Owned by Institutions9.88%
Financial Efficiency
Tvardi Therapeutics’s return on equity (ROE) is 15.43 and return on invested capital (ROIC) is -139.18%.
Return on Equity (ROE)15.43
Return on Assets (ROA)-1.62
Return on Invested Capital (ROIC)-139.18%
Return on Capital Employed (ROCE)-1.40
Revenue Per Employee419.82K
Profits Per Employee-4.17M
Employee Count17
Asset Turnover0.16
Inventory Turnover0.90
Valuation Ratios
The current PE Ratio of Tvardi Therapeutics is ―. Tvardi Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value-1.62
Price to FCF―
Price to Operating Cash Flow-7.32
PEG Ratio―
Income Statement
In the last 12 months, Tvardi Therapeutics had revenue of 7.14M and earned -70.87M in profits. Earnings per share was -46.59.
Revenue7.14M
Gross Profit6.33M
Operating Income-55.78M
Pretax Income-71.27M
Net Income-70.87M
EBITDA-62.60M
Earnings Per Share (EPS)-46.59
Cash Flow
In the last 12 months, operating cash flow was -31.58M and capital expenditures 0.00, giving a free cash flow of -31.58M billion.
Operating Cash Flow-31.58M
Free Cash Flow-31.58M
Free Cash Flow per Share-3.37
Dividends & Yields
Tvardi Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.02
52-Week Price Change162.41%
50-Day Moving Average25.66
200-Day Moving Average19.62
Relative Strength Index (RSI)64.48
Average Volume (3m)24.97K
Important Dates
Tvardi Therapeutics upcoming earnings date is Aug 14, 2025, TBA (Confirmed).
Last Earnings DateMay 12, 2025
Next Earnings DateAug 14, 2025
Ex-Dividend Date―
Financial Position
Tvardi Therapeutics as a current ratio of 11.03, with Debt / Equity ratio of 0.77%
Current Ratio11.03
Quick Ratio10.81
Debt to Market Cap5.96
Net Debt to EBITDA-0.10
Interest Coverage Ratio-6.58
Taxes
In the past 12 months, Tvardi Therapeutics has paid -398.00K in taxes.
Income Tax-398.00K
Effective Tax Rate<0.01
Enterprise Valuation
Tvardi Therapeutics EV to EBITDA ratio is -0.22, with an EV/FCF ratio of -0.23.
EV to Sales1.96
EV to EBITDA-0.22
EV to Free Cash Flow-0.23
EV to Operating Cash Flow-0.23
Balance Sheet
Tvardi Therapeutics has $40.99M in cash and marketable securities with $254.00K in debt, giving a net cash position of -$40.74M billion.
Cash & Marketable Securities$40.99M
Total Debt$254.00K
Net Cash-$40.74M
Net Cash Per Share-$4.34
Tangible Book Value Per Share-$3.02
Margins
Gross margin is 97.54%, with operating margin of -781.57%, and net profit margin of -992.95%.
Gross Margin97.54%
Operating Margin-781.57%
Pretax Margin-998.53%
Net Profit Margin-992.95%
EBITDA Margin-877.12%
EBIT Margin-879.81%
Analyst Forecast
The average price target for Tvardi Therapeutics is $60.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$60.60
Price Target Upside99.08% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast-40.16%
EPS Growth Forecast78.28%